List of Excipients in Branded Drug LIVALO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kowa Pharmaceuticals America Inc	LIVALO	pitavastatin calcium	66869-104	HYPROMELLOSE
Kowa Pharmaceuticals America Inc	LIVALO	pitavastatin calcium	66869-104	LACTOSE MONOHYDRATE
Kowa Pharmaceuticals America Inc	LIVALO	pitavastatin calcium	66869-104	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE

LIVALO Excipient Strategy and Commercial Opportunities for Pitavastatin

Last updated: October 1, 2026

LIVALO is the U.S. brand for pitavastatin calcium, a small-molecule HMG-CoA reductase inhibitor marketed by Kowa Pharmaceuticals America. Its commercial protection is no longer primarily driven by active-ingredient exclusivity. The most credible opportunities are differentiated solid oral formulations, excipient substitutions that improve tolerability or manufacturability, and patient-focused delivery formats that can support a new drug application or 505(b)(2) strategy.

The core formulation opportunity is narrow. Pitavastatin is already available as low-dose immediate-release tablets, and generic pitavastatin products compete on price. A new entrant therefore needs a measurable clinical, adherence, manufacturing, or market-access advantage rather than a cosmetic reformulation.

What excipients are used in LIVALO tablets?

LIVALO tablets use a conventional immediate-release oral formulation with a relatively compact excipient system. The U.S. prescribing information identifies the principal inactive ingredients as lactose monohydrate, low-substituted hydroxypropyl cellulose, hypromellose, magnesium aluminometasilicate, magnesium stearate, colloidal silicon dioxide, titanium dioxide, and triacetin. Colorants can vary by strength and market presentation. (Kowa Pharmaceuticals America, 2023; DailyMed, 2024)

Formulation element	Likely function	Commercial relevance
Lactose monohydrate	Diluent and tablet mass builder	Creates a lactose-free substitution opportunity
Low-substituted hydroxypropyl cellulose	Disintegrant and dry binder	Supports rapid tablet breakup
Hypromellose	Binder or film-forming polymer	Controls tablet integrity and coating performance
Magnesium aluminometasilicate	Adsorbent, carrier, and flow aid	Can influence content uniformity and compression
Magnesium stearate	Lubricant	Excess levels can slow wetting and dissolution
Colloidal silicon dioxide	Glidant and moisture-management aid	Supports powder flow and process robustness
Titanium dioxide and colorants	Appearance and strength differentiation	Low strategic value unless linked to patient usability
Triacetin	Film-coating plasticizer	Supports coating flexibility and appearance

The exact composition of generic pitavastatin tablets may differ. Generic manufacturers can use alternative excipients if the product meets the applicable pharmaceutical equivalence, dissolution, stability, and bioequivalence requirements.

What formulation characteristics create opportunities around pitavastatin?

The most valuable formulation targets are dose uniformity, rapid disintegration, lactose avoidance, tablet size reduction, and improved administration for patients who have difficulty swallowing.

Pitavastatin is administered at low doses, commonly 1 mg, 2 mg, and 4 mg. Low-dose products create a higher relative risk of content-uniformity problems when the active ingredient is poorly distributed through the blend. An excipient system that improves particle deagglomeration, ordered mixing, or direct compression can reduce process variability.

The principal technical opportunities are:

1. Lactose-free tablets. A formulation using mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler could target patients with lactose intolerance, formulary restrictions, or excipient preferences.

2. Smaller tablets. Higher-density fillers and optimized granulation can reduce tablet volume while retaining acceptable hardness and rapid disintegration.

3. Fast-disintegrating tablets. Crospovidone, croscarmellose sodium, sodium starch glycolate, or engineered co-processed excipients could support a faster dissolution profile.

4. Sprinkle or dispersible products. A formulation suitable for dispersion in water or administration with soft food could address swallowing limitations. This would require careful control of dose recovery, taste, chemical stability, and food compatibility.

5. Orally disintegrating tablets. An ODT could target older adults and patients taking multiple chronic medicines. The commercial value would depend on whether the dosage form improves adherence or access sufficiently to justify a premium.

6. Moisture-robust tablets. Pitavastatin products may benefit from low-moisture processing and packaging because moisture can alter powder flow, tablet hardness, disintegration, and stability.

How should an excipient strategy address pitavastatin’s low-dose presentation?

Low-dose uniformity should be the central development criterion.

A formulation team should evaluate the active ingredient’s particle-size distribution, crystal form, surface area, electrostatic behavior, and tendency to segregate from larger excipient particles. Ordered mixing or wet granulation may provide better uniformity than simple direct blending, but granulation increases process complexity and can introduce moisture exposure.

A rational screening program would compare:

Development route	Primary benefit	Main risk
Direct compression with microcrystalline cellulose	Low process cost and simple scale-up	Segregation and content-uniformity risk
Dry granulation	Low moisture exposure and improved flow	Ribbon variability and tablet-density differences
Wet granulation	Strong granules and improved blend uniformity	Stability, drying, and process-cost burden
Co-processed excipient platform	Better flow, compression, and disintegration balance	Supplier dependence and higher material cost
Spray-dried carrier system	Potentially improved dispersion and dissolution	Scale-up and residual-moisture control

For a 1 mg product, the active load is particularly small. A formulation that uses a premix or engineered carrier may improve blend uniformity, but the process must prevent active segregation during transfer, compression, and packaging.

What lactose-free excipient opportunities exist for LIVALO?

Lactose replacement is the clearest patient-facing opportunity because the current brand formulation contains lactose monohydrate.

Potential diluent systems include:

• Mannitol for a clean mouthfeel and suitability for orally disintegrating formats.
• Microcrystalline cellulose for compactability and tablet strength.
• Dibasic calcium phosphate for high-density direct compression.
• Isomalt or xylitol for fast-dissolving and palatable dosage forms.
• Coprocessed cellulose-based excipients for combined binding, flow, and disintegration performance.

Each alternative creates tradeoffs. Mannitol can produce a cooling sensation and may require moisture-control measures. Microcrystalline cellulose can increase tablet volume. Dibasic calcium phosphate may affect dissolution and may be less suitable for some coating systems. Polyols can create hygroscopicity or gastrointestinal tolerability issues at higher loads.

A lactose-free product should be positioned around a documented patient or market-access need. A label statement alone is unlikely to justify a meaningful premium in a mature generic market.

What formulation patents could protect a new pitavastatin product?

A patentable formulation should rely on a defined technical feature, not merely the substitution of one conventional excipient for another.

Potential claim categories include:

Composition claims

Claims could cover pitavastatin calcium with a defined combination of filler, disintegrant, binder, lubricant, and glidant, provided the combination produces a non-obvious technical result. Broad claims to conventional excipient combinations are vulnerable to anticipation and obviousness challenges.

Performance claims

More defensible claims may define:

• Dissolution within a specified time interval.
• Content-uniformity limits across a batch.
• Disintegration time below a defined threshold.
• Stability after accelerated storage.
• Reduced tablet size at a specified hardness.
• Improved dissolution under discriminatory conditions.

Performance limitations need credible comparative data against LIVALO and representative generic products.

Process claims

Process claims may cover:

• Premixing pitavastatin with a carrier.
• Controlled-order addition of lubricant.
• Dry granulation conditions.
• Moisture-controlled compression.
• Particle-size engineering.
• Specific coating or drying parameters.

Process claims can create manufacturing barriers, but enforcement is more difficult when the process is not visible in the finished product.

Packaging claims

A moisture-protective blister, desiccant configuration, or unit-dose package may support a narrow patent position when the package produces a documented stability advantage. Packaging claims alone rarely create durable market exclusivity unless the product has a significant stability problem.

When does LIVALO lose exclusivity, and what is the generic risk?

LIVALO’s principal commercial risk is generic substitution. Pitavastatin is a small molecule, so the relevant competitive pathway is abbreviated new drug approval under section 505(j), not biosimilar approval under the Public Health Service Act.

LIVALO was approved by the FDA in 2009 under NDA 22-363. The product is available in 1 mg, 2 mg, and 4 mg tablets. (FDA, 2009) Generic pitavastatin products have entered the U.S. market, which confirms that the core commercial barrier has been breached.

Risk category	Assessment for LIVALO
Active-ingredient patent risk	Limited as a barrier to ordinary generic entry
Formulation patent risk	Relevant only if a listed or enforceable claim covers the marketed product
Method-of-use risk	Potentially relevant for specific indications, but weak against ordinary substitution if not required for labeling
Regulatory exclusivity	No current biologic exclusivity issue; small-molecule exclusivity periods have elapsed
Biosimilar risk	Not applicable
Generic substitution	High
Premium pricing	Difficult without a differentiated dosage form or distribution channel

The current Orange Book should be used to confirm active listings, expiration dates, pediatric extensions, and any unexpired patent claims associated with the specific LIVALO NDA. Patent and exclusivity status can change through delisting, expiration, litigation, or regulatory action. (FDA, 2024)

What FDA pathway is available for a differentiated pitavastatin formulation?

A conventional generic with the same dosage form and route would generally pursue an ANDA. A materially different formulation may require a 505(b)(2) NDA if the sponsor relies in part on FDA findings for pitavastatin but introduces a new dosage form, formulation, route, or labeling condition. (FDA, 1999)

Potential 505(b)(2) products include:

• Orally disintegrating pitavastatin.
• A dispersible tablet for patients with dysphagia.
• A modified-release product.
• A pediatric-friendly liquid or suspension.
• A fixed-dose combination containing pitavastatin and another cardiovascular medicine.

The regulatory case is strongest where the new formulation addresses a defined limitation of the reference product. The sponsor would need to establish pharmaceutical quality, stability, dose delivery, and, depending on the change, comparative bioavailability or clinical bridging.

An ODT is not automatically eligible for reduced development. A new dosage form can require substantial work on in vitro performance, food effects, taste masking, dose uniformity, packaging, and patient administration.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue several opportunities without owning the finished drug product.

Co-processed excipient systems

A supplier could develop a platform optimized for low-dose direct compression. The value proposition would be improved flow, reduced segregation, and consistent tabletability across the 1 mg, 2 mg, and 4 mg strengths.

Lactose-free carrier systems

A premix designed for low-dose pitavastatin could combine mannitol or microcrystalline cellulose with a disintegrant and glidant. The supplier would need to control particle-size distribution and demonstrate compatibility with pitavastatin calcium.

ODT and taste-masking systems

Taste-masking excipients, ion-exchange resins, polymer coatings, and porous mannitol systems could support an ODT or dispersible tablet. Pitavastatin’s low dose makes taste masking technically manageable, but bitterness, grittiness, and dose recovery remain product-development issues.

Film-coating platforms

A ready-to-use coating system could reduce manufacturing complexity and provide color differentiation without relying on the original formulation. The strongest opportunity would combine low moisture permeability with short coating time and reliable appearance across strengths.

Stability and packaging systems

Desiccant-integrated blister materials, high-barrier films, and unit-dose packaging could support stability claims and improve adherence. This opportunity is more attractive for mail-order, long-term-care, and specialty pharmacy channels than for standard retail generics.

How does the commercial opportunity compare with other statins?

Pitavastatin competes with high-volume generic statins, including atorvastatin, rosuvastatin, simvastatin, and pravastatin. These alternatives have broader generic penetration and strong payer leverage.

Product	Generic maturity	Differentiation opportunity	Excipient opportunity
Pitavastatin	High	Low-dose, tolerability, lactose-free, dysphagia	Moderate
Atorvastatin	Very high	Combination and pediatric formats	Low to moderate
Rosuvastatin	Very high	Combination and low-dose formats	Low to moderate
Pravastatin	Very high	Geriatric and administration formats	Moderate
Simvastatin	Very high	Combination products	Low

Pitavastatin may retain commercial relevance in patients who require an alternative statin regimen or who are concerned about interactions and tolerability. The excipient strategy should support that clinical positioning without making unsupported claims about superior tolerability.

What licensing and partnership models are realistic?

The most practical licensing targets are:

1. A co-processed excipient platform licensed to a generic manufacturer.
2. A complete lactose-free pitavastatin formulation licensed under a development or supply agreement.
3. An ODT or dispersible product partnered with a company experienced in 505(b)(2) development.
4. A high-barrier packaging system supplied under a quality and technical agreement.
5. A fixed-dose cardiovascular combination developed with a commercial partner.

A finished-product license is more attractive when it includes formulation patents, process know-how, stability data, and scalable manufacturing. An excipient-only license has lower regulatory risk but also weaker exclusivity unless the excipient system materially improves product performance.

What generic launch scenarios exist for an improved pitavastatin product?

Three launch models are commercially plausible.

Low-cost ANDA generic

This model competes on supply reliability and price. It has limited value for a differentiated excipient strategy because the payer market generally rewards the lowest-cost equivalent product.

Premium formulation

A lactose-free, smaller, dispersible, or ODT product could support a higher price if it solves a documented administration or access problem. The product would likely require stronger clinical and human-factors evidence than a standard tablet.

Institutional and specialty distribution

Unit-dose packaging, dysphagia-friendly administration, or improved stability could target long-term-care facilities, hospital discharge programs, mail-order pharmacies, and adherence programs. These channels may value packaging and administration benefits more than retail pharmacy buyers.

Key Takeaways

• LIVALO contains a conventional immediate-release pitavastatin calcium tablet formulation with lactose monohydrate and standard compression and coating excipients.
• Generic competition limits the value of an ordinary excipient substitution.
• The strongest opportunities are lactose-free tablets, low-dose content-uniformity platforms, ODTs, dispersible tablets, and moisture-robust packaging.
• A patent strategy should focus on measurable performance, defined excipient combinations, manufacturing controls, or stability advantages.
• Standard same-formulation products generally fit the ANDA pathway. Materially different dosage forms may require a 505(b)(2) NDA.
• Biosimilar risk does not apply because pitavastatin is a small-molecule drug.
• Excipient suppliers can create value through co-processed carriers, taste-masking systems, ready-to-use coatings, and high-barrier packaging.
• The commercial case is strongest when the formulation solves dysphagia, lactose avoidance, low-dose uniformity, or adherence problems.

FAQs About LIVALO Excipients and Formulation Opportunities

Is LIVALO lactose-free?

No. The U.S. LIVALO formulation identifies lactose monohydrate as an inactive ingredient. A lactose-free pitavastatin product could be differentiated through an alternative filler system, subject to pharmaceutical equivalence and regulatory requirements.

Can a generic manufacturer use different excipients from LIVALO?

Yes. An ANDA product may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and safety.

Is there a biosimilar version of LIVALO?

No. LIVALO contains pitavastatin, a small-molecule active ingredient. Competing products are generics, not biosimilars.

Would an orally disintegrating pitavastatin tablet qualify for automatic generic substitution?

Not necessarily. A different dosage form may require a separate regulatory pathway, potentially including a 505(b)(2) NDA rather than an ordinary ANDA.

Can excipients alone create a strong patent position for pitavastatin?

Usually not. Conventional substitutions are vulnerable to obviousness challenges. A stronger position requires unexpected performance, a defined formulation architecture, a specialized manufacturing process, or a demonstrated stability and administration benefit.

References

1. DailyMed. (2024). Pitavastatin calcium tablet: U.S. prescribing information and inactive ingredients. U.S. National Library of Medicine.

2. Food and Drug Administration. (1999). Applications covered by section 505(b)(2). U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2009). LIVALO (pitavastatin calcium) tablets, NDA 22-363: Approval package and prescribing information. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. Kowa Pharmaceuticals America, Inc. (2023). LIVALO (pitavastatin) tablets: Prescribing information. Montgomery, Alabama.